Design Therapeutics, Inc. (DSGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

RBC Capital analyst Leonid Timashev maintained a Hold rating on Design Therapeutics (DSGN – Research Report) today and set a price target of $5.00. The company’s shares opened today at $4.87.

Looking for the best graphic design software? We tested out a range of apps for beginners, professionals, and enthusiastic creatives and these are our top picks whatever you're working on.

Can two rivals, bringing Robert Indiana’s long-hidden work into the light, reboot his legacy for a new generation? By Julia Halperin This year’s show pays elegant, effusively colorful ...

Contemporary sweat baths reflect the country’s architectural past — and propose a future in which simple, sustainable buildings can still be sublime. By Michael Snyder and Luana Rigolli The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Design Therapeutics, Inc. before investing. In this article, we go over a few key ...